nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)
|
Yule, Alexander |
|
|
23 |
5 |
p. 984-990 |
artikel |
2 |
An emotional journey: caregiver experiences with gastrostomy tube decision-making for children with cystic fibrosis
|
Dickinson, Kimberly M. |
|
|
23 |
5 |
p. 1000-1006 |
artikel |
3 |
Are demographic findings really possible from reports in a spontaneous reporting system?
|
Noguchi, Yoshihiro |
|
|
23 |
5 |
p. 1031 |
artikel |
4 |
Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
|
Baker, Elizabeth |
|
|
23 |
5 |
p. 959-966 |
artikel |
5 |
Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis
|
Jia, Shijing |
|
|
23 |
5 |
p. 878-884 |
artikel |
6 |
Azithromycin reduces bronchial wall thickening in infants with cystic fibrosis
|
Chen, Yuxin |
|
|
23 |
5 |
p. 870-873 |
artikel |
7 |
Beyond insulin: Unraveling the complex interplay of ER stress, oxidative damage, and CFTR modulation in CFRD
|
Umashankar, Bala |
|
|
23 |
5 |
p. 842-852 |
artikel |
8 |
Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor
|
Gavey, Roderick |
|
|
23 |
5 |
p. 1024-1026 |
artikel |
9 |
Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies
|
Kowalik, Aleksandra |
|
|
23 |
5 |
p. 1027-1030 |
artikel |
10 |
Comparative sensitivity of early cystic fibrosis lung disease detection tools in school aged children
|
Bayfield, Katie J |
|
|
23 |
5 |
p. 918-925 |
artikel |
11 |
Concentrations of dehydroepiandrosterone-sulphate (DHEA-S) in people with cystic fibrosis on and off elexacaftor-tezacaftor-ivacaftor
|
Abid, Shadaan |
|
|
23 |
5 |
p. 874-877 |
artikel |
12 |
Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor
|
Vonk, Steffie E.M. |
|
|
23 |
5 |
p. 1007-1009 |
artikel |
13 |
Demographic factors associated with within-individual variability of lung function for adults with cystic fibrosis: A UK registry study
|
Palma, Marco |
|
|
23 |
5 |
p. 936-942 |
artikel |
14 |
Direct healthcare costs in the first 2 years of life: A comparison of screened and clinically diagnosed children with cystic fibrosis – The Irish comparative outcomes study of CF (ICOS)
|
Somerville, Rebecca |
|
|
23 |
5 |
p. 896-902 |
artikel |
15 |
Education, employment, and income among people living with cystic fibrosis across three decades – A matched cohort study using Danish health registries
|
Jensen, Camilla Bjørn |
|
|
23 |
5 |
p. 836-841 |
artikel |
16 |
E-learning within the European cystic fibrosis society - A multidisciplinary cross-sectional survey
|
Smith, C. |
|
|
23 |
5 |
p. 1020-1023 |
artikel |
17 |
Elexacaftor/tezacaftor/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis
|
Pioch, Charlotte O. |
|
|
23 |
5 |
p. 863-869 |
artikel |
18 |
Estimating minimal clinically important difference (MCID) for gastrointestinal symptoms in cystic fibrosis
|
Lee, MinJae |
|
|
23 |
5 |
p. 991-999 |
artikel |
19 |
Feasibility and accuracy of at-home glucose tolerance tests for cystic fibrosis related diabetes screening
|
Alexandre-Heymann, Laure |
|
|
23 |
5 |
p. 857-862 |
artikel |
20 |
Gut microbiota in adults with cystic fibrosis: Implications for the severity of the CFTR gene mutation and nutritional status
|
Durda-Masny, Magdalena |
|
|
23 |
5 |
p. 977-983 |
artikel |
21 |
Health care resource utilization preceding death or lung transplantation in people with cystic fibrosis
|
Guyot, Erika |
|
|
23 |
5 |
p. 903-909 |
artikel |
22 |
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
|
Semenchuk, Julie |
|
|
23 |
5 |
p. 815-822 |
artikel |
23 |
Impact of day-to-day variation in FEV1 on measures of change: A conceptual description
|
Magaret, Amalia S. |
|
|
23 |
5 |
p. 943-946 |
artikel |
24 |
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
|
Marsh, Ryan |
|
|
23 |
5 |
p. 967-976 |
artikel |
25 |
Impact of interruption of CFTR modulator therapies
|
Capraz Yavuz, Burcu |
|
|
23 |
5 |
p. 947-949 |
artikel |
26 |
Lung structural and functional impairments in young children with cystic fibrosis diagnosed following newborn screening – A nationwide observational study
|
Frauchiger, Bettina S. |
|
|
23 |
5 |
p. 910-917 |
artikel |
27 |
Measuring the burden of cystic fibrosis: A scoping review
|
Cheema, Zain M. |
|
|
23 |
5 |
p. 823-830 |
artikel |
28 |
News article
|
|
|
|
23 |
5 |
p. 813-814 |
artikel |
29 |
Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis
|
Chhibber, Anindit |
|
|
23 |
5 |
p. 1010-1019 |
artikel |
30 |
Quantifying abnormal alveolar microstructure in cystic fibrosis lung disease via hyperpolarized 129Xe diffusion MRI
|
Bdaiwi, Abdullah S. |
|
|
23 |
5 |
p. 926-935 |
artikel |
31 |
Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience
|
Santhakumar, Anjali |
|
|
23 |
5 |
p. 853-856 |
artikel |
32 |
Symptoms and quality of life in adults with cystic fibrosis: A cross-sectional analysis of the InSPIRe:CF trial
|
Smirnova, Natalia |
|
|
23 |
5 |
p. 831-835 |
artikel |
33 |
Table of Content
|
|
|
|
23 |
5 |
p. i-iii |
artikel |
34 |
The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis
|
Lupas, Daniel |
|
|
23 |
5 |
p. 950-958 |
artikel |
35 |
Widespread alterations in systemic immune profile are linked to lung function heterogeneity and airway microbes in cystic fibrosis
|
Rossi, Elio |
|
|
23 |
5 |
p. 885-895 |
artikel |